Company profile

Schrodinger

Drug Discovery & Development

Company profile

About Schrodinger

Schrödinger is a computational platform company that transforms the way therapeutics and materials are discovered through physics-based molecular modeling and simulation. Founded over 30 years ago, the company has built an industry-leading software platform that combines advanced computational chemistry, molecular dynamics, machine learning, and predictive modeling to accelerate molecular discovery across life sciences and materials science applications. The company's flagship products include Maestro (unified modeling environment), Glide (ligand-receptor docking), FEP+ (free energy calculations), LiveDesign (collaborative design platform), Desmond (molecular dynamics), and Jaguar (quantum chemistry). These tools enable computational chemists, medicinal chemists, and materials scientists to predict molecular properties, optimize drug candidates, and design novel materials with greater speed and accuracy than traditional experimental methods alone. Schrödinger serves a diverse customer base spanning biotech and pharmaceutical companies, academic institutions, and materials science organizations across aerospace, automotive, consumer packaged goods, semiconductors, and specialty chemicals industries. The company's technology addresses critical challenges in small molecule drug discovery, antibody design, peptide discovery, enzyme engineering, drug formulation, polymeric materials, organic electronics, catalysis, and pharmaceutical formulations. Beyond its software business, Schrödinger operates its own therapeutics discovery group that leverages the platform to advance a proprietary pipeline of drug candidates. Current clinical programs include SGR-1505, a MALT1 inhibitor that has received Fast Track designation for relapsed/refractory Waldenström Macroglobulinemia, and SGR-3515, a Wee1/Myt1 inhibitor. The company's mission is to improve human health and quality of life by transforming therapeutic and materials discovery through computational innovation.

Company description Schrodinger official website

Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Schrodinger?

Claim this profile to manage Company information and connect with the Health AI Central audience.

Claim this listing

01 · Operating footprint

Where the Company operates

Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.

Clinical focus

  • MALT1-related conditions
  • Relapsed/Refractory Waldenström Macroglobulinemia
  • Wee1/Myt1-related oncology indications

Who it serves

  • Academic institutions
  • Aerospace
  • Automotive
  • Biotech & Pharmaceutical
  • Consumer Packaged Goods
  • Oil & Gas
  • Semiconductor
  • Specialty Chemicals

Deployment & integration

Cloud Saas · Hybrid · On Premise · Other deployment with recorded integration context.

Geographic context

MarketsNot currently listed
Company sourceOfficial website

Company milestones

Platform expansion

SGR-1505 received Fast Track designation; Phase 1 clinical data for SGR-1505 presented at EHA Annual Congress; Multiple inducement grants reported under Nasdaq rules in 2026

Partnerships

Recorded partners

  • Morphic Therapeutic

02 · Flagship portfolio

Products, workflows, and platform capabilities

Selected source-backed Company products and the available commercial context.

BioLuminate

Antibody and biologics modeling platform

Software · On PremiseCompany source

Desmond

Molecular dynamics simulation engine

Software · On PremiseCompany source

FEP+

Free energy calculations for drug design

Software · On PremiseCompany source

Glide

Industry-leading ligand-receptor docking solution

Software · On PremiseCompany source

LiveDesign

Collaborative molecular design platform

Platform · Cloud SaaSCompany source

Maestro

Complete modeling environment for molecular discovery

Platform · HybridCompany source

Modeling Services

High-velocity entry point to the Schrödinger platform

Service · OtherCompany source

MS Maestro

Materials science modeling environment

Platform · HybridCompany source

03 · Research intelligence

Research Intelligence evidence

Publications, preprints, clinical validation, and regulatory records in Evidence Position order.

04 · Company-reported outcomes

Outcomes and case studies

Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.

High enrichment in virtual screening

Glide docking across diverse receptor types

Accurate pose predictions

Ligand-receptor docking with explicit water modeling

Fast Track designation

SGR-1505 for Waldenström Macroglobulinemia treatment

Morphic Therapeutic

Design of a novel small molecule inhibitor of α4β7 integrin using digital chemistry strategy

05 · Leadership

Leadership team

Leadership profiles and professional links from the current Company record.

No active leadership profiles are currently listed.

06 · Company updates

Updates from Schrodinger

Recent articles published on Schrodinger's official website.

No Company updates are currently listed.

07 · HAIC coverage

Coverage and analysis

Health AI Central reporting that mentions this Company.

08 · Official presence

Company sources and channels

Curated official destinations from the active Company record.

09 · Market pathway

Additional Companies in this Market

Other active Companies in the same market, selected alphabetically from the HAIC directory.

Market context

Drug Discovery & Development

Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.

Explore the full market directory or compare this Company with additional active profiles.

View all Companies in this market

10 · Pro research

Coming soon

Expanded Company research is in development.

Health AI Central Pro · Coming Soon

Deeper Company research is coming soon.

Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.

ResearchEvidence analysis

Linked research, clinical, and regulatory source pathways.

CompanyTechnical context

Expanded product, deployment, integration, and partnership research.

MethodSource & review record

Record-level provenance and review context.

Coming Soon